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ABSTRACT
Fascinating earlier evidence suggests an intrinsic capacity of human natural killer (NK) cells to acquire
adaptive immune features in the context of cytomegalovirus (CMV) infection or pro-inflammatory cytokine
stimulation. Since the role of memory NK cells in cancer has so far remained elusive and adoptive NK cell
transfer in relapsing pediatric acute B cell precursor leukemia (BCP-ALL) patients awaits improvement, we
asked the question whether tumor-priming could promote the generation of memory NK cells with
enhanced graft-vs.-leukemia (GvL) reactivity. Here, we provide substantial evidence that priming of naive
human NK cells with pediatric acute B cell leukemia or acute myeloid leukemia specimens induces a
functional conversion to tumor-induced memory-like (TIML)-NK cells displaying a heightened tumor-
specific cytotoxicity and enhanced perforin synthesis. Cell cycles analyses reveal that tumor-priming
sustainably alters the balance between NK cell activation and apoptosis in favor of survival. In addition,
gene expression patterns differ between TIML- and cytokine-induced memory-like (CIML)-NK cells with the
magnitude of regulated genes being distinctly higher in TIML-NK cells. As such, the tumor-induced
conversion of NK cells triggers the emergence of a so far unacknowledged NK cell differentiation stage
that might promote GvL effects in the context of adoptive cell transfer.
Abbreviations: BCP-ALL, Acute B cell precursor leukemia; CIML-NK cells, Cytokine-induced memory-like NK cells;
GMP, Good Manufacturing Process; GO, Gene ontology; GvL, Graft-versus-Leukemia; IS, Immunological synapse; KIR,
Killer-immunoglobulin like receptor; NCR, NK cell receptor; NSG, NOD.Cg-Prkdcscid IL2rgtmWjl/Sz mice; TIML-NK cells,
Tumor-induced memory-like NK cells
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Recent data indicate that pediatric BCP-ALL may under certain
conditions, such as low MHC class I expression,1 high expres-
sion of ligands to major activating NK cell receptors2 and
existing mismatches on the killer-immunoglobulin like receptor
(KIR)-KIR ligand (KIRL) level,3,4 emerge as a target of
“alloreactive” NK cells. However, the results of early phase I/II
clinical studies using the adoptive transfer of allogeneic NK
cells in the non-transplant or transplant setting to pediatric
BCP-ALL patients have so far been disappointing, and adoptive
NK cell transfer protocols warrant further evaluation and
presumably optimization.5
Intriguingly, earlier reports suggest an intrinsic capacity of
NK cells to acquire adaptive immune features and to display
augmented functionality.6-8 Hallmarks of such adaptive
immune responses have been the detection of NK cell-mediated
recall responses in hapten-sensitized T and B cell-deficient
Rag2¡/¡ mice,6,7 and the appreciation of a protective transfer-
able NK cell-mediated immunity in a murine cytomegalovirus
(MCMV)-infection model.8 In line with this, human CMV-spe-
cific memory NK cells have been detected in healthy carrier
individuals9 or in transplant recipients upon HCMV reactiva-
tion.10,11 Moreover, adaptive immune features of NK cells have
also been elicited independent from prior exposure to viral
antigens by conditioning mouse or human NK cells in the pres-
ence of IL12 and IL18, resulting in the generation of cytokine-
induced memory-like (CIML)-NK cells.12-14
As the role of memory NK cells in cancer has indeed been
postulated but so far remained elusive, we questioned whether
tumor-priming in the absence of vigorous pro-inflammatory
cytokine stimulation might promote the generation of memory
NK cells that could sustain graft-vs.-leukemia (GvL) reactivity.
Here, we provide substantial evidence that tumor-priming
induces a functional conversion of NK cells that triggers a
tumor-specific NK cell recall response, which is distinct from
other forms of immunologic NK cell memory. Collectively, our
data strongly support the proof of concept that the overall
modest GvL effects of NK cells toward pediatric BCP-ALL or
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AML can experimentally be augmented, and as such the gener-
ation of TIML-NK cells adds an exciting new perspective to the
design of future experimental adoptive NK cell transfer
protocols.
Results
TIML-NK cells exhibit superior, tumor-specific in vitro
functionality
To examine the exploitation of adaptive immune features of
NK cells, we started our experiments by priming primary NK
cells with pediatric BCP-ALL or AML specimens (Fig. 1A).
Our protocol included priming with irradiated specimens such
as the pediatric BCP-ALL cell line NALM-16, the primary
BCP-ALL specimens P3B and P31G or primary AML speci-
mens P18R and P84D as well as cultivation in the presence of
low dose, good manufacturing process (GMP)-compatible IL2
and IL15 to facilitate the implementation of a tumor-priming
step into future adoptive cell transfer protocols. We chose these
primary specimens as the clinical course of the patients was
judged to be representative of high-risk pediatric BCP-ALL and
AML (early death after first relapse). Phenotypic analyses
revealed that the specimens differed with respect to the expres-
sion of important NK cell receptor (NCR) ligands, namely
NKG2D ligands (NKG2D-L), ICAM-1, HLA-E, HLA-class I
and DNAM-1 ligands (Fig. S1). To assess the potential clinical
efficacy in case of experimental adoptive cell transfer, we
included IL12/18-primed CIML-NK cell preparations12-14 as a
“gold standard” in all experiments.
In vitro cytotoxicity assays on day 7 (d7, see Supplemental
Methods for details) demonstrated that tumor-primed primary
NK cells exhibit a significantly enhanced cytotoxic function not
only toward the BCP-ALL cell line NALM-16, but also toward
the two different primary pediatric BCP-ALL specimens P3B
and P31G when compared with control NK cells (Fig. 1B).
Importantly, improved NK cell function was also demonstrable
upon priming with the primary pediatric acute myeloid leuke-
mia (AML) samples P18R or P84D (Fig. 1C). As early phase I/
II clinical trials exploit either adoptive transfer of feeder-
expanded NK cells15,16 or occasionally the transfer of the bona
fide large granular lymphocyte lymphoma cell line NK-92,17 we
Figure 1. Tumor-priming induces TIML-NK cells to elicit a superior, tumor-restricted functionality against pediatric BCP-ALL and AML. (A) Experimental layout for in vitro
generation of TIML-NK cells. Freshly isolated NK cells were primed on d-1 with different irradiated tumor specimens, irradiated PBMCs or with a mixture of 10 ng/mL IL12
and 50 ng/mL IL18. All NK cell preparations were cultured in medium supplemented with low dose (100 IU/mL) IL2 and low dose (1 ng/mL) IL15. Cytotoxicity was tested
on d7. (B) BCP-ALL-primed TIML-NK cells exhibit heightened anti-tumor functionality toward pediatric BCP-ALL. In vitro cytotoxicity assays on d7. Unprimed (“control NK
cells”), BCP-ALL (NALM-16-, P3B- or P31G)-primed (“TIML-NK cells”) and IL12/IL18-primed (“CIML-NK cells”) NK cells were used as effectors and the identical tumor speci-
men was used as a target for re-stimulation on d7. Data represent 10 (NALM-16 priming/re-stimulation), 7 (P3B-priming/re-stimulation) or 5 (P31G-priming/re-stimula-
tion) different donors (E:T ratio 3:1 in NALM-16 and P3B experiments, E:T ratio 9:1 in P31G experiments). (C) AML-primed TIML-NK cells exhibit heightened anti-tumor
functionality toward the identical pediatric AML. In vitro cytotoxicity assays on d7. Unprimed, AML (P18R- or P84D)-primed and IL12/IL18-primed NK cells were used as
effectors and the identical tumor specimen was used as a target for re-stimulation on d7. Data represent 5 (P18R priming/re-stimulation) or 3 (P84D-priming/re-stimula-
tion) different donors (E:T ratio 3:1 in all experiments). (D) Priming-induced NK cell conversion requires exposure to malignant cells. NK cells from donors depicted in
Fig. 1B (NALM-16-priming) were primed with irradiated allogeneic PBMCs at a ratio of 1:3. In vitro cytotoxicity assays performed on d7 with control or PBMC-primed NK
cells as effectors and NALM-16 cells as targets. Results represent data from six different NK cell-donors primed with 5 different PBMC specimens (E:T ratio 1:1). (E) NALM-
16-primed TIML-NK cells do not exert cytotoxicity toward non-malignant PBMCs. In vitro cytotoxicity assays were performed on d7 with NALM-16-primed NK cells as effec-
tors and autologous or allogeneic PBMCs as targets. Data represent three different donors (E:T ratio 1:1). (F) TIML-NK cells show heightened cytotoxicity only toward the
original priming tumor entity. Unprimed, NALM-16-, P31G-, P3B- or P18R-primed and IL12/IL18-primed NK cells were used as effectors; as indicated other tumor speci-
mens were used targets for re-stimulation on d7 to test functional TIML-NK cell specificity. Note, that the donors shown in Fig. 1F are identical to the respective donors
tested in Fig. 1B and C, i.e., the efficacy of the priming effect was documented for every donor shown in Fig. 1F. Data represent 3 (NALM-16 priming/Kasumi-1 re-stimula-
tion), 5 (P31G priming/NALM-16 re-stimulation), 3 (P3B priming/P18R re-stimulation) or 4 (P18R priming/P3B re-stimulation) different donors. E:T ratio 3:1 (all experi-
ments). All experiments were performed in triplicates. p < 0.01, p < 0.001.
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next tested whether generation of memory-like features would
also be feasible in these NK cell preparations. Therefore, we
used K562-(mb)IL15-41BBL-expanded NKAES cells (see Sup-
plemental Methods for details on the NK cell activation and
expansion system18) or the NK-92 cell line and performed
NALM-16 priming and re-stimulation on d7 (see Supplemental
Methods). Although a certain increase in NK cell cytotoxicity
was demonstrable for both preparations (Fig. S2), this effect
was not statistically significant, indicating that memory-like
cell conversion is unlikely to occur in extensively cytokine-
stimulated or in malignantly-transformed NK cells.
As peripheral blood mononuclear cells (PBMCs) of various
donors tested in Fig. 1B were not able to convert NK cells to
memory-like NK cells (Fig. 1D), and as TIML-NK cells did not
exert cytotoxicity toward autologous or allogeneic PBMCs
(Fig. 1E), we consider the initiation of uncontrolled NK cell
activation or the induction of relevant autoimmune responses
of NK cells toward non-malignant cells to be highly unlikely.
Figure 2. TIML-NK cells confer anti-leukemic activity toward pediatric BCP-ALL and AML in vivo. (A) Experimental layouts for in vivo experiments. Blasts of the donors P3B
(BCP-ALL) or P18R (AML) were injected on d0 into NSG mice followed by a second injection of the varying NK cell preparations as indicated several hours later on d0. Leu-
kemic burden was quantified in the bone marrow 17 d later. Exemplified gating strategy for identification of the leukemic load shown as human CD19C blasts (for the
BCP-ALL P3B) or human CD33C (for the AML P18R) relative to murine CD45C cells, respectively. Data from BCP-ALL (P3B)-tumor induction represent n D 10 mice injected
with control NK cells (three different donors), n D 9 mice injected with TIML-NK cells (three different donors) primed with P3B blasts, n D 6 mice injected with TIML-NK
cells (two different donors) primed with P18R blasts and n D 6 mice injected with CIML-NK cells (two different donors). Note, that the P18R-primed TIML-NK cells used in
the P3B experiment (first row) exhibited a significant priming effect when tested toward P18R (second row). Data from AML (P18R)-tumor induction represent n D 9 mice
injected with control NK cells (three different donors), n D 9 mice injected with TIML-NK cells (three different donors) primed with P18R blasts and n D 5 mice injected
with CIML-NK cells (two different donors). (B) Experimental layout for serial transplantations to address residual leukemic load after adoptive NK cell transfer. Pooled BM
samples of one of the donors from adoptive NK cell transfer experiments in P3B-induced mice depicted in Fig. 2A was re-injected into groups of naive mice (n D 3; 20 £
106 per mouse). Shown is the gating strategy and the leukemic P3B-burden in the BM on d56. Data represent 1 experiment. p < 0.05, p < 0.01, p < 0.001.
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Most interestingly, NK cells exhibited improved antitumor
properties on d7 only toward the original priming-tumor entity
NALM-16, P3B, P31G or P18R, respectively, but not toward
pediatric BCP-ALL and AML specimens other than the one
used for priming (Fig. 1F). Thus, we conclude from these data
that tumor-priming induces memory NK cell conversion in a
tumor-specific manner.
TIML-NK cells confer anti-leukemic activity toward
pediatric BCP-ALL and AML in vivo
Having shown that tumor-priming initiates the generation of
TIML-NK cells, which exhibit a superior tumor-specific in vitro
cytotoxicity, we next assessed the efficacy of TIML-NK cell-
mediated GvL responses in vivo. To this end, we adoptively
transferred in vitro primed TIML-NK cells into immune-
deficient NOD.Cg-Prkdcscid IL2rgtmWjl/Sz (NSG) mice that had
been previously injected with P3B or P18R and quantified the
resulting leukemic burden. In primary (Fig. 2A) as well as in
serial engraftment experiments (Fig. 2B), TIML-NK cells
primed with P3B significantly reduced leukemic burden in
P3B-bearing mice. In contrast, TIML-NK cells primed with the
AML P18R did not reduce leukemic load in P3B-bearing mice
but instead reduced P18R load, thus confirming the tumor-
specificity of TIML-NK cells in vivo (Fig. 2A). Interestingly
enough, IL12/IL18-primed CIML-NK cells exhibited a
significant cytotoxic function both in P3B-bearing but also in
P18R-bearing mice even in the absence of whole body irradia-
tion19 or systemic IL2 supplementation16 (Fig. 2A). In line with
the assumption that the clinically relevant effect of adoptive
NK cell transfer occurs very early after cell injection, NK cells
were not any longer present at the time of euthanasia. Although
TIML-NK cells did not sustain tumor regression as shown by
serial engraftment experiments, the observed in vivo efficacy is
nevertheless striking given that cytotoxicity toward P3B in our
in vitro experiments was about 30% (Fig. 1B) and GvL activity
of NK cells toward BCP-ALL is known to be low.3,4
TIML-NK cells show phenotypical characteristics of
advanced maturity
Examination of surface markers revealed a
CD56brCD94hiCD16hiCD57intKLRG1intinhKIRint phenotype
and as such TIML-NK cells comprise an intermediate stage
Figure 3. TIML-NK cells show phenotypical signs of advanced maturity. Phenotypical characterization of (A) NK cell activation, (B) ontogenesis and (C) chemokine recep-
tors of unprimed, NALM-16-, P3B-, P18R-, CTV-1 and IL12/IL18-primed NK cells on d7. NK cell preparations were subjected to flow cytometric quantification of the propor-
tion of cells expressing the given receptors. Bars represent the mean percentage of the respective receptorCCD56CCD3¡ NK cell subsets, error bars display SD. Note, that
the CD56 receptor is not included in this diagram as all cells were gated on CD56 before subset analysis. Results represent data from 14 different donors for control, 7
donors for NALM-16-primed, 4 donors for P3B-primed, 4 donors for P18R-primed, 4 donors for CTV-1-primed and 6 donors for IL12/IL18-primed NK cells. Displayed p val-
ues refer to comparison between primed NK cell preparations and control NK cells. p< 0.05, p < 0.01.
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between the less mature CD94hiCD57¡inhKIR¡ and the fully
mature CD94¡CD57CinhKIRC NK cell subset20,21 irrespective
of the priming tumor entity as shown for NALM-16, P3B and
P18R (Fig. 3A–C). In line with published data reporting pheno-
typical similarities between resting and memory NK cells22 but
in contrast to NK cells primed with the T-ALL cell line CTV-
1,23 TIML-NK cells exhibited a quiescent phenotype overall
resembling features of control NK cells, indicating that pheno-
typical conversion is obviously not mandatory for functional
re-programming. Interestingly, TIML-NK cells lacked
significant upregulation of NK cell markers like CD25, which is
abundantly expressed in CIML-NK cells14,24 and HCMV-spe-
cific memory NK cells,25 CD94/NKG2C and/or CD57 which
have been associated with memory NK cell formation in
CMV-infected humans10,26 or KLRG1 and CXCR6 observed in
murine virus/hapten-specific memory NK cells.7,8 Thus, we do
not find any evidence for a clonal expansion of one specific NK
cell compartment in the context of tumor encounter.
“Tumor-priming” promotes NK cell survival
To further examine TIML-NK cell homeostasis and the
capability for dynamic responses, we performed cell-based
assays and analyzed cell cycle, viability rates and resulting cell
numbers during cultivation. Cell cycle analysis provided
evidence that tumor-priming rapidly induces TIML-NK cells to
leave the G0/G1 interphase and enter the S-phase, where DNA
replication occurs (Fig. 4A). As a result, TIML-NK cells are as
early as on d0 able to proceed to mitosis (G2/M phase), i.e. to
successfully proliferate, and rapidly return to non-diving cells
as demonstrated by the low frequency of cells in the G2/M
phase on d7. In contrast, the response of CIML-NK cells is
delayed until d3 and although CIML-NK cells indeed leave the
interphase and are able to enter the S phase, only few
CIML-NK cells accomplish to proceed to the G2/M phase
(Fig. 4A). Classifying viable NK cells as 7-AAD¡/AnnexinV¡,
early apoptotic NK cells as 7-AAD¡/AnnexinVC and late
Figure 4. “Tumor-priming” promotes NK cell survival. (A–C) Cell cycle analyses, viability assays and cell numbers were obtained on control, NALM-16-primed TIML- and
CIML-NK cells at the indicated time points. (A) Cell cycle analyses evaluating BrdU incorporation. Cells incorporating BrdU are shown relative to their phase in the cell cycle
(i.e., G0/G1, S, or G2/M phase) as assessed by quantifying 7-AAD staining intensities. Results represent data from four different donors (mean§ SD). (B) Cell viability assays
using 7-AAD/AnnexinV staining. Cell populations are characterized as being viable (7-AAD-/AnnexinV-), early apoptotic (7-AAD¡/AnnexinVC) and late apoptotic (7-AADC/
AnnexinVC). Exemplified gating strategy of one representative donor and mean values of the % positive NK cells in the 7-AAD/AnnexinV experiments. Data display four
different donors. (C) Cell counts. Shown is the number of CD56CCD3¡ cells normalized to the number of control NK cells as “fold increase”; error bars represent SD. Data
represent 10 donors on d3 and 17 donors on d6. p < 0.05, p < 0.01, p < 0.001.
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apoptotic NK cells as 7-AADC/AnnexinVC, we were able to
demonstrate that TIML-NK cells exhibited/maintained a high
rate of viability with little proneness to apoptosis on d7 of cul-
ture, whereas a high proportion of CIML-NK cells were ren-
dered apoptotic (Fig. 4B). In line with previously published
data27 and with the notion that high expression of the activa-
tion marker CD25 is per se associated with increased AnnexinV
binding,28 we attribute the extensive rate of apoptosis in CIML-
NK cells to the induction of an IL12-mediated “activation-
induced cell death” (AICD). As a result of this apparently
shifted cell balance between proliferation and apoptosis the
total cell number of TIML-NK cells was upregulated (d3: fold
increase 1.53 § 0.47, proliferation >> apoptosis) but virtually
unchanged in CIML-NK cells (d3: fold increase 1.0 § 0.25,
proliferation D apoptosis) (Fig. 4C). Overall, the amplitude of
TIML-NK cell expansion as determined by cell counting was
comparatively modest but mirrors analogous responses
recorded in classical models of MCMV infection8 or in poly I:
C-stimulated mice bearing adoptively transferred CIML-NK
cells.29 Collectively, our data promote the concept that tumor-
priming does initiate mitosis, prevents apoptosis and strongly
alters the balance between NK cell activation and apoptosis in
favor of survival. Based on this characteristic kinetics, we there-
fore propose the term tumor-induced “memory-like” instead of
“memory” NK cells to avoid a potentially misleading compari-
son to in vivo generated virus or hapten-specific NK cells or
memory CD8C T cells.
TIML-NK cells display enhanced perforin synthesis
Intrigued by the finding of increased antitumor functionality
conferred by TIML-NK cells, we next performed intracellular
staining to examine the capacity of TIML-NK cells to express
IFNg, synthesize perforin or granzyme-B and trigger degran-
ulation. Boolean gating revealed an increased number of one
and two responses in TIML-NK cells (Fig. S4). Interestingly
and in contrast to virus-specific memory NK cells,8,30,31 and
CIML-NK cells12,14,19,24 that preferably secrete IFNg follow-
ing re-activation, TIML-NK cells synthesized more perforin
but not IFNg upon tumor re-encounter (Fig. 5A, Fig. S5). In
support of this finding confocal imaging (see Supplemental
Methods) provided evidence for elevated total perforin
content per cell in TIML- as compared with control NK cells
(Fig. 5B and C). TIML-NK cells maintained microtubule-
Figure 5. Perforin synthesis is enhanced in TIML-NK cells following contact to pediatric BCP-ALL. (A) NALM-16-primed d7 NK cells together with the respective controls
were stained after re-stimulation with NALM-16 to determine the functional response in terms of cytokine synthesis, ability for degranulation and perforin synthesis.
CD56CCD3¡ NK cells were gated and the relative frequency of cells positive for perforin, CD107a, IFNg and granzyme-B was analyzed. Data represent 10 donors for per-
forin (except CIML-NK cells with 7 donors), 6 for CD107a, 8 for IFNg and 3 for granzyme-B. (B) Representative confocal microscopy images of conjugates formed between
NALM-16 cells and control NK cells (top panel), NALM-16-primed TIML-NK cells (middle panel) or between NALM-16 cells and CIML-NK cells (bottom panel), E:T ratio of
3:1. Images are z-projections, except the BF, which is a single image taken at the plane of the glass; scale bar D 5 mm; BF D bright field. Note that the NK cell shape is
extended and flattened toward the immunological synapse (white arrowheads) and forms multiple F-actin rich, cytoplasmic projections (red arrowheads). Data are repre-
sentative of three independent experiments using three different NK cell donors. (C) Quantitative analysis of conjugate formation demonstrating total perforin per cell
measured by intensity sum of perforin fluorescence, distance of MTOC to synapse per cell (Polarization) and mean distance of lytic granule to MTOC (Convergence) per
cell. Data in C represent three different NK cell donors in three independent experiments (mean § SD). p < 0.05, p < 0.01.
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organizing center (MTOC) polarization, however, the mean
distance of lytic granules to the MTOC (convergence)
increased in both TIML- and CIML-NK cells (Fig. 5C). As
granule convergence to the MTOC is an early step in the
preparation of an NK cell for cytotoxicity32,33 this is an
unexpected finding; however, movement and exocytosis of
secretory lysosomes in NK cells can occur independently
from MTOC polarization.32,34-36 As direct visualization of
conjugate formation clearly documents an extension and
flattening of TIML-NK cell shape toward the immunological
synapse (IS) (Fig. 5B, white arrowheads) and formation of
multiple F-actin-rich cytoplasmic projections (Fig. 5B, red
arrowheads), our observations indeed argue for a more
efficient IS formation by TIML-NK cells, particularly in view
of the propensity for degranulation and the documented
improved cytotoxicity.
Figure 6. Transcriptome analysis reveals significant differences in the signature of TIML- and CIML-NK cells. (A) Heat map and unsupervised hierarchical clustering. Unsu-
pervised hierarchical cluster analysis using the Euclidean distance of the 100 most variable probes of the data set demonstrates the pronounced inter-donor variability
but also the significant differences in the signature of NALM-16-primed TIML- and CIML-NK cells. Red indicates lower and yellow indicates higher expression values. For
gene identification see also Table S1. (B) Vulcano Plots. Shown is the log fold change (x-axis) plotted against the significance (y-axis, negative log10), respectively, in
NALM-16-primed TIML-NK cells and CIML-NK cells plotted on unprimed NK cells. Probes with significant changes and considerable magnitude of change (log fold change
of more than ¡0.5/0.5) are marked in blue and are identified in the Tables S2-S5. The dashed red line indicates the significance threshold of p D 0.05. (C) GO Terms. Dif-
ferentially expressed GO terms of NALM-16-primed TIML-NK cells {upper graph} in relation to unprimed NK cells and CIML-NK cells {lower graph} in relation to unprimed
NK cells. Shown is a selection of differentially expressed cellular components (top 12), biologic processes (top 40) and molecular functions (top 30). Gray bars represent
the regulated gene count and the point plot represents the –Lg (p value) of the respective GO term. Data in A–C represent one experiment performed with four donors.
Validation of selected genes is shown in Fig. S5.
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TIML-NK cells express a distinct transcriptome signature
To identify contingent differences in the process of TIML- or
CIML-NK cell conversion, we further performed transcriptome
analysis of all NK cell preparations (Fig. 6, Fig. S5). In line with
the notion that NK cell functionality may significantly differ
between various donors, we observed a significant inter-individ-
ual variability irrespective of any preceding priming in selected
genes encoding for particular interleukins, interleukin receptors,
chemokine ligands, CD86, MHC class II and killer immuno-
globulin-like receptors (Fig. 6A, Table S1). However, based on
the analysis of Euclidean distances, significant differences also
existed in the signature of TIML- and CIML-NK cells (Fig. 6B,
Table S2–S5, Fig. S5). Consistent with our theoretical assump-
tion that tumor-priming should induce a more complex conver-
sion of NK cells than triggering of pro-inflammatory receptors
alone, the extent of gene regulation was distinctly higher in
TIML-NK cells (Fig. 6C). Both TIML- and CIML-NK cells
showed regulated gene expression in the area of cellular compo-
nents, particularly in the GO term “membrane part” (i.e., regu-
lation of chemokine or cytokine receptors such as CXCR6,
IL17RA, CCR7 or IL18RAP), however, only TIML-NK cells dis-
played a significant alteration in the regulation of genes that are
involved in “metabolic processes” (i.e., CYP1B1, ALDOC,
TKTL1, AGMAT, VDR). Collectively, the putative transcrip-
tional changes (Table S2–S5) that emerge during the generation
and re-programming of TIML-NK cells reveal a unique gene
expression pattern and hence we propose that TIML-NK cells
are distinct from other forms of memory-like NK cells.
Discussion
In light of the modest GvL effects that NK cells are able to exert
toward pediatric BCP-ALL and recent evidence suggesting an
intrinsic capacity of NK cells to acquire adaptive immune fea-
tures, we here sought to explore memory-like characteristics of
NK cells in the context of tumor-priming. Collectively, our
data provide evidence of a tumor-initiated and tumor-specific
NK cell recall response, which is associated with enhanced per-
forin synthesis but not IFNg secretion. Thus, our data strongly
indicate that the formation of TIML-NK cells resembles a so
far unacknowledged mode of functional memory-like NK cell
conversion.
Adaptive immune features of human NK cells have so far
been described in HCMV-infection9-11,25,26,31,37-42 or upon pro-
inflammatory cytokine stimulation.13,14,24,31 To our knowledge,
an enhancement of NK cell functionality via tumor-priming
has only been described in the context of priming with the
CTV-1 cell line, where target cell lysis is critically dependent on
CD69 triggering23 and STAT5 signaling,43 and for feeder (i.e.,
RPMI8866, Epstein-Barr lymphoblastoid cell line or K562)
expanded NK cells. As enhanced cytotoxicity for tumor-acti-
vated NK cells (T-ANKs) and feeder-expanded NK cells is lim-
ited to the immediate post-priming period, is critically
dependent on extensive activation and is non-selective, we feel
that both do not bear features of adaptive NK cells and are
therefore not comparable to TIML-NK cells.
Focusing on human CIML-, TIML- and HCMV-specific
memory NK cells, we observe certain similarities but more
importantly significant differences (Table 1). Most striking are
the differences concerning “clonal origin” and “means of func-
tionality." In line with the finding for an antigen-driven oligo-
clonal expansion of human CMV-specific NK cells,9,37 the
phenotype of CMV-induced memory NK cells has reported to
be biased toward a CD94/NKG2CCNKG2A¡CD57CaKIRC
phenotype.9-11,38,39,41 In contrast, neither CIML- nor TIML-NK
cells show signs of a distinct phenotype or clonality (Fig. 3).13,24
Considering that CIML-NK cell conversion is initiated via
Table 1. Overview of various forms of human memory NK cells. CNS: conserved non-coding sequence, DAB2: Disabled homolog 2, EAT-2: Ewing’s sarcoma-associated
transcript 2, IKZF2: IKAROS Family Zinc Finger 2, PLZF: Promyelocytic leukemia zinc finger protein, SYK: Spleen tyrosine kinase.
CIML-NK cells TIML-NK cells HCMV-induced memory NK cells
Mode of generation Brief exposure to IL 12/IL15/IL18 (16hrs) Priming with irritated tumor specimen CMV infection/reactivation
Phenotype Not distinct Not distinct Distinct
CD25hi CD94hi NKG2Ahi CD69hi NKp46hi CD56br CD94hi CD16hi CD57int KLRG1int
inhKIRint
CD94/NKG2Chi CD57hi CD25hi NKG2A-
KIR2DL2C, KIR2DS2C, KIR2DS4Cand/or
KIR3DS1C
Functional characteristics IFN-g production " (upon re-
stimulation with cytokines or K562)
Multiple cytokine responses " Capacity to produce IFN-g "
Anti-tumor cytotoxicity vs AML " In virto cytotoxicity " Host protection
Tumor growth #
Involved cytokines IL12, IL18 / IL12, type I IFNs
Antigen dependence / Unlikely C (CMV-encoded protiens)
Clonal expansion Unlikely / CCC
Proliferation CC C CC
Mode of contraction CC (apoptosis) (C) (apoptosis) ?
Epigenetic modulation C ? C
Presumed mechanism Epigenetic remodeling of the IFNG
CNS1
Perforin production " (upon tumor re-
stimulation)
Stochastic epigenetic modulation of the
FcRg– NK cell subset
Synapse formation likely to be
improved
Antibody-dependent selection /
expansion of FcRg– NK cell subset
Epigenetic imprinting of the IFN-g locus
Involved NCR ? ? NKG2C, NKp46, DNAM1, aKIRs, 2B4
Involved NCR ligands ? ? HLA-E
Signalling molecules IL2-CD25-Stat5 signalling ? Multi-protien deficient (SYK, DAB2,
EAT-2, PLZF, IKZF2)
Quotes (13, 14, 19, 24, 29, 31) / (9, 10, 25, 26, 31, 37 - 42)
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IL12/IL18 receptor activation,13,24 while TIML-NK cells pre-
sumably convert upon recognition of subtle, net changes in
activatory, inhibitory and triggering receptor expression, a
solely antigen-mediated process is in both instances highly
unlikely.
With respect to the means of functionality both human
CIML-NK cells and HCMV-specific memory NK cells dis-
play a propensity for IFNg secretion and through this exert
antitumor properties 13,14,19 or contribute to anti-viral host
defense.26,31,40 In contrast, we detected a higher perforin
accumulation upon BCP-ALL tumor re-encounter and an
overall increased number of one and two cell responses in
TIML-NK cells (Fig. 5A, Fig. S4). Together with the observa-
tion that TIML-NK cells flatten toward the IS and form F-
actin-rich cytoplasmic projections (Fig. 5B and C), our data
favor the concept of a more efficient perforin synthesis as a
result of improved IS formation. In fact, we may even have
underestimated the propensity of TIML-NK cells for synapse
formation as the imaging studies do not accurately allow
quantifying the time span that a particular NK cell is in con-
tact with a tumor cell. Hence, it is difficult to draw firm con-
clusions about whether multiple transient contacts or rather
a prolonged interaction might have caused the improved
functional response seen in TIML-NK cells. In line with this
notion, it has earlier been demonstrated that fixed time-point
analyses rather underestimate NK cell cytotoxicity as burst
kinetics and spatial coordination during serial killing are not
accounted for.44
Here, we document increased functionality of TIML-NK
cells toward a repertoire of phenotypically heterogeneous pedi-
atric BCP-ALL, but also AMLs specimens expressing different
pools of NK cell receptor ligands at variable levels. Thus, the
identification of one individual NCR–NCR ligand axis that
might have initiated TIML-NK cell conversion was highly
unlikely. And indeed, although we were able to identify mecha-
nisms that sustain improved TIML-NK cell functionality, the
intracellular signal transduction mechanisms initiating TIML-
NK cell conversion remain elusive. Preliminary own data indi-
cate that the NKG2D-NKG2DL axis might play a role in
TIML-NK cell generation (data not shown). However, despite
significant NKG2D expression on TIML-NK cells (Fig. 3A) the
NKG2D-L expression on our BCP-ALL and AML specimens
was variable or in one instance absent (P31G) (Fig. S1), and we
did not observe any downregulation of the NKG2D receptor on
TIML-NK cells secondary to tumor contact (data not shown).
Together with the existing evidence that sustained exposure to
NKG2D-L expressing tumor cells may indeed render NK cells
dysfunctional,45,46 our data do not support a significant contri-
bution of the NKG2D-NKG2DL axis in the induction of
tumor-induced memory NK cell formation. In addition, we
were neither able to detect IL15 in our culture supernatants
(data not shown) nor did we find any evidence for upregulated
pSTAT1, three or five expression in TIML-NK cells (Fig. S3).
Considering IL15 being dispensable for the expansion and for-
mation of memory NK cells in MCMV infection8 and the
notion that excessive availability of IL15 may even erode the
pool of memory progenitors,47 the IL15-JAK3-STAT5-depen-
dent pathway, therefore, is also unlikely responsible for TIML-
NK cell conversion.
Consistent with our difficulties to identify a single responsi-
ble signal transduction pathway initiating the emergence of
TIML-NK cell and our assumption that tumor-priming pre-
sumably induces a complex re-programming of NK cells,
TIML-NK cells showed a distinct signature in their transcrip-
tome expression, particularly in the areas of “membrane parts”
and “metabolic processes” (Fig. 6C). Interestingly, gene annota-
tion revealed IL26 to be the gene most upregulated (Table S2)
and PDGF-A to be the gene most downregulated (Table S3) in
TIML-NK cells as compared with control NK cells. As IL26
mediates both proliferative as well as anti-apoptotic effects48
and induces TH1 polarization,
49 it is tempting to speculate that
IL26 secreted by TIML-NK cells might modulate subsequent
adaptive immune responses. On the other hand, the platelet-
derived growth factor-A (PDGF-A) has so far not been associ-
ated with NK cell function; however, downregulation of the
corresponding c-Kit / PDGF receptor on dendritic cells indeed
effectively improves NK cell-triggering.50 Thus, our data sug-
gest that in addition to enhanced direct anti-tumor cytotoxicity,
TIML-NK cells might also sustain successive adaptive immune
responses and perpetuate in vivo antitumor immunity.
Confining the definition of memory to a functional con-
sequence and rather not to the recognition of a limitless
number of antigens, we here propose to include tumor rec-
ognition as sufficient to initiate memory-like cell formation
of NK cells, as TIML-NK cells are verifiably unique in
terms of cell cycle kinetics (Fig. 4), means of functionality
(Fig. 5) and gene expression pattern (Fig. 6). Despite obvi-
ous differences to CIML-NK cells and HCMV-induced
memory NK cells, TIML-NK cells intriguingly display simi-
larities to the “homeostatic proliferation-induced memory
NK cells” growing in lymphopenic hosts.22 Although the
evidence for this form of NK cell memory has so far been
confined to mice,22and it has not yet been demonstrated
that proliferation-induced memory NK cells display a
higher functionality upon re-stimulation, the similarities to
TIML-NK cells are nevertheless striking. Notably, both pop-
ulations develop in the absence of other immune cells, may
as a result of missing self-MHC class I (i.e., KIR ligands)
acquire a somewhat “unlicensed” status, display a quiescent
phenotype, similar proliferation and contraction kinetics
and a certain longevity. The finding that adaptive NK cells
such as TIML-NK cells, “homeostatic proliferation-induced
memory NK cells” and murine CIML-NK cells all lack a
distinct phenotype is in contrast to memory T cells that dif-
ferentiate into distinct subsets of either central memory or
effector memory phenotype. At this point, we may only
speculate whether the current concept of memory cell gen-
eration, which is built on studies of adaptive immunity that
results from antigen-specific immune recognition is really
applicable to innate immune cells.
In view of the fact that our numerous NK cell donors were
not selected according to their known basic NK cell cytotoxic
performance or according to existing mismatches on the KIR-
KIRL level, our data provide strong support for the proof of
concept that the overall modest GvL effects of NK cells toward
pediatric BCP-ALL can significantly be exploited and aug-
mented (Fig. 1B and C, Fig. 2A). Thus, we introduce an exciting
new perspective to future protocols of experimental adoptive
ONCOIMMUNOLOGY e1317411-9
NK cell transfer. Previous efforts to improve existing cell trans-
fer strategies harness the potential of somewhat “naive” NK
cells for activation and/or expansion, and include the optimiza-
tion of donor selection, the application of ex vivo or in vivo
cytokine stimulation, the use of antibodies to induce antibody-
dependent cellular cytotoxicity or to block inhibitory KIRs and
the introduction of chimeric antigen receptors.5 In contrast, the
exploitation of adaptive immune features of NK cells entails the
advantage that it is presumably based on cellular re-program-
ming; however certainly at the expense of having smaller num-
bers of transferable effector cells at one`s disposal.
Henceforth, various questions remain to be answered as to
what the role of antigen-dependent receptor-ligand interactions
is, which signal transduction mechanisms realize enhanced per-
forin secretion/synapse formation and control cell cycle kinet-
ics and, finally, whether unique pathways exist that ensure
memory NK cell formation in the context of tumor encounter.
Maybe one way to achieve a truly patient-tailored and individu-
alized treatment strategy will be the design of a two-step proto-
col comprising as a first step memory NK cell conversion via
tumor-priming followed by a second step of accomplishing
ample activation and expansion.
Materials and methods
Generation of “memory-like” NK cells
PBMCs from healthy volunteer donors were used with
informed consent to isolate primary NK cells via negative selec-
tion (EasySep Human NK cell Enrichment Kit, STEMCELL
Technologies). For tumor-priming, NALM-16 cells or primary
blasts of donors P3B, P31G, P18R and P84D were irradiated
with 100 Gy and added on day -1 to the respective NK cell
preparation (E:T ratio of 1:3). Written informed consent was
obtained from the parents of the donating children in accor-
dance with the Declaration of Helsinki and after approval by
the local ethics committee. The cell lines were originally
obtained from ATCC, Wesel, Germany, and passaged more
than 50 times. Thawing and Mycoplasma testing was last per-
formed in September 2016. For cytokine-priming NK cells
were pre-activated for 16 h (on day -1) with a mixture of
10 ng/mL IL12 (PeproTech) and 50 ng/mL IL18 (Medical &
Biological Laboratories) as described before.13 All NK cell prep-
arations were cultured in medium supplemented with low dose
(100 IU/mL) IL2 (Novartis) and low dose (1 ng/mL) IL15 (Cell-
Genix) (from hereon called complete medium) from day -1 to
ensure survival. After 16 h, all NK cell preparations were
washed and replaced in complete medium, which was refreshed
on day 3 and 6 of culture. For microscopy studies, TIML-NK
cells were additionally purified by negative selection using the
human NK cell isolation kit on day 2 to eliminate potentially
surviving NALM-16 cells or cell debris. As cultivation condi-
tions resulted to a small extent (<5%) in the activation and
expansion of CD3C T and CD3CCD56C NKT cells, all prepara-
tions were depleted from residual CD3C cells on day 6 of cul-
ture using EasySep Human CD3 Positive Selection Kit I or
EasySep Human NK cell Enrichment Kit (STEMCELL
Technologies (95% CD56C cells, 0.3% CD3C). Priming was
performed in primary NK and NK-92 cells on day -1 of the
culture and in expanded NK cells (see below) on day 7 of the
14-day expansion course. In further experiments, primary NK
cells were primed with 100 Gy irradiated allogeneic PBMCs on
day -1 (E:T ratio of 1:3).
Flow-cytometric analyses
Immunophenotyping of tumor-primed NK cells: The following
antibody clones were used for phenotypical NK cell characteri-
zation: CD3 (UCHT1), CD16 (3G8), CD25 (2A3), CD56
(HCD56), CD57 (NK-1), CD69 (L78), CD94 (HP-3D9),
CD158a/b/e (HP-3E4), CD161 (HP-3G10), CD186 (K041E5),
NKp30 (Z25), NKp44 (Z231), NKp46 (9E2/NKp46), NKG2D
(BAT221), NKG2A (Z199), NKG2C (134591) and KLRG1
(generated by HP Pircher, Freiburg, Germany). The percentage
of CD56CCD3¡ cells expressing each antigen was determined
using cluster analysis.
Cell cycle analyses: NK cell preparations were incubated in
the presence of 10 mM BrdU for 16 h in complete medium.
Cell cycle analysis was performed using the BD Pharmingen
FITC-BrdU Flow Kit according to the manufacturer’s protocol
(BD Biosciences). Co-staining with 7-AAD hereby allows the
enumeration and characterization of cells that are actively syn-
thesising DNA in terms of their respective position in the cell
cycle.
Viability assays: NK cell preparations were counted by vital
dye exclusion with trypan blue (Sigma-Aldrich) and stained
with antibodies against NK cell surface markers, 7-AAD (BD
Biosciences) and AnnexinV (BioLegend) according to the man-
ufacturer’s protocol.
Functional NK cell response staining: NK cell prepara-
tions were co-cultured for 6 h with NALM-16 (E:T ratio of
1:3) in the presence of CD107a antibody (H4A3) and
GolgiPlug (BD Biosciences). Subsequently, NK cells were
stained with the indicated NK cell surface antibodies, per-
meabilized and co-stained with the respective intracellular
antibodies against perforin (dG9), IFNg (B27) and gran-
zyme-B (GB11).
Conjugate formation
NK cells (4.5 £ 105) were mixed with NALM-16 cells
(1.5 £ 105) and incubated in FACS tubes at 37 C and 5%
CO2 for 15 min. Conjugates were then transferred to silane-
coated microscope slides and stained with the respective
antibodies or dyes. For further information concerning
staining protocols and confocal microscopy refer to supple-
mental methods.
Transcriptome analysis
RNA pre-amplification, labeling and hybridization onto
Human Genome U133Plus 2.0 GeneChip arrays (Affyme-
trix) was performed according to standard manufacturer’s
protocols. Expression array data were background corrected
and normalized by the GC robust multi-array Average (GC-
RMA) method and log transformed using Bioconductor
packages simpleaffy and affy. Unsupervised hierarchical
clustering was based on the Euclidean distance. Pairwise
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comparisons were conducted using t-test controlling at a
p value level of 0.05. Pathway and gene ontology analyses
were performed using the Database for Annotation, Visuali-
zation and Integrated Discovery (DAVID) database system
of the NIH.
Adoptive NK cell transfer into NOD.Cg-Prkdcscid IL2rgtmWjl/
Sz mice
NOD.Cg-Prkdcscid IL2rgtmWjl/Sz (NSG) mice were purchased
at “The Jackson Laboratory” and maintained under specified
pathogen-free conditions in the research animal facility of
the University of Tuebingen, Germany. All experimental
animal procedures were conducted according to German
federal and state regulations using unirradiated, 8–12 week-
old male NSG mice. For adoptive NK cell transfer, 4 £ 106
blasts of patients P3B or P18R were intravenously injected
into unirradiated NSG mice on day 0, followed by a second
injection of NK cell preparations (5 £ 106 cells) later on day
0. On day 17, NSG mice were killed and BM preparations
were subjected to flow-cytometric analysis using formerly
defined leukemia surface markers. For serial transplantation,
pooled 20 £ 106 BM cells of group 1 and 2, respectively, of
the former P3B-adoptive NK cell transfer experiments
shown in Fig. 2A (resembling approximately 6 £ 105 leuke-
mic cells in group 1 or 3 £ 105 leukemic cells in group 2)
was intravenously re-injected into naive NSG mice to verify
residual leukemic load after adoptive NK cell transfer. On
day 56, NSG mice were killed and BM preparations were
subjected to flow-cytometric analysis. The following anti-
body clones were used in this experiment: CD19 (SJ25C1),
CD33 (WM53), CD45 (HI30), CD56 (HCD56) and anti-
mouse CD45 (30-F11).
Statistics
Mean values and SD from experiments analyzing two condi-
tions were determined using an unpaired two-tailed Student’s
t-test. A p value < 0.05 was considered statistically significant.
If the p value is not specified, the indicated results have not
been statistically significant.
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